Clinical Research Of The Treatment Of Deficiency Of Nephorjing Type2 Hypertension With Zuogui-Wan Decoction

Object:linical Observation Zuogui-wan to kidney essence deficiency hypertension(Ⅱ period), and to explore the mechanism of the party, to evaluate its efficacy and safety. It intends to provide the actual valuable therapeutic approach for the clinical treatment of hypertension Methods:Selected in accordance with inclusion and exclusion criteria of Shandong University of Traditional Chinese Medicine First Affiliated Hospital of outpatient and inpatient comprehensive medical cases, 60 cases were randomly divided into experimental group and control group 30 cases. Generally the two groups were not statistically different. Use of western medicine control group treated with losartan, the experimental group and traditional Chinese medicine decoction Zuogui-wan losartan in treatment based on day one, sooner or later, half an hour after a meal, warm clothes. Clinical assessment of efficacy after 4 weeks. Before treatment, underwent a general examination items: pulse, respiration, blood pressure, heart rate, liver function, renal function, electrocardiogram and other tests, ambulatory blood pressure effect was observed before and after the two groups of patients assessed the severity of symptoms, TCM total symptom score, The total effect of traditional Chinese medicine, determine the efficacy of individual symptoms to evaluate the efficacy and safety.Results:The study found that Zuo Gui-wan can significantly lower blood pressure levels in patients, compared to clinical efficacy in the treatment group in the control group had no significant difference in blood pressure; the severity of clinical symptoms controlled, experimental group than the control group(P <0.05); two Compare the efficacy of Chinese medicine single patient symptoms, the test group than the control group(P <0.05); total score of TCM symptom contrast, the test group than the control group(P <0.05); comparing the total effect of traditional Chinese medicine, the test group than the control group(P <0.05). Overall comparison, the test group than the control group. No significant changes in the liver and kidney function before and after treatment safety indicators(P> 0.05), application security.